Skip to content

Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes

Real-TICA Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes. Evaluation of Antiplatelet Therapy After 12 Months in Patients Undergoing PCI and Treated With Ticagrelor During the Acute Phase of an ACS.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02265068
Acronym
Real-TICA
Enrollment
700
Registered
2014-10-15
Start date
2014-08-31
Completion date
2016-12-31
Last updated
2018-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome (ACS)

Keywords

Acute coronary syndrome (ACS), Ticagrelor

Brief summary

Documentation of long-term data regarding ticagrelor use and evaluation of reasons for discontinuation of ticagrelor in patients with ACS

Detailed description

REAL-TICA is a retrospective non-interventional study to assess the long-term use of ticagrelor in patients with ACS and to evaluate the reasons for discontinuation of ticagrelor. For this purpose, selected sites from the ALKK-PCI registry and the respective patients will be identified. The sites' eligibility for this study includes the frequent use of ticagrelor during the acute phase of ACS. Eligible patients are characterised by the diagnosis of ACS and the use of ticagrelor during PCI. The eligible sites will be contacted by IHF and asked to contact their eligible patients by letter to obtain informed consent of the patients for the planned 12M follow-up by IHF. A detailed questionnaire on events within the last 12 months, current symptoms, current medication and the use of ticagrelor will be added to the patients' letters. Patients then are asked to return their responses on consent to participate in the study as well as the filled in questionnaire to IHF. Alternatively, patients may choose to receive a telephone call by IHF to answer the detailed questionnaire in person. In case of essential information missing, IHF will contact the primary care physician of the patient directly to obtain information about clinical events and medications.

Interventions

DRUGTicagrelor

Treatment of ACS patients with Ticagrelor

Sponsors

IHF GmbH - Institut für Herzinfarktforschung
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 * ACS (STEMI or NSTE-ACS) with PCI * Ticagrelor treatment during the acute phase * Written informed consent for participation in the study.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Treatment outcomes of ACS patients receiving Ticagrelor12 monthsDocumentation of Events for ACS patients treated with Ticagrelor with follow-up over 12 months

Secondary

MeasureTime frameDescription
Long-term use and premature discontinuation of Ticagrelor treatment12 monthsDocumentation of time span during which Ticagrelor is taken by patient

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026